Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVALF NASDAQ:CVRX NASDAQ:INGN NYSEAMERICAN:STXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVALFCovalon Technologies$1.89-1.0%$1.84$1.46▼$3.08$51.82M0.544,480 shs1,430 shsCVRXCVRx$8.32-0.3%$6.39$4.30▼$18.55$217.16M1.23306,705 shs95,863 shsINGNInogen$6.45-3.4%$6.64$5.70▼$13.33$173.80M1.66242,439 shs64,426 shsSTXSStereotaxis$2.32-2.7%$2.18$1.54▼$2.72$199.09M1.44339,199 shs220,703 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVALFCovalon Technologies-1.05%-1.05%+9.88%+9.88%+25.29%CVRXCVRx-1.18%+19.97%+47.53%+33.60%-14.01%INGNInogen+2.14%-8.62%+3.09%-2.05%-30.56%STXSStereotaxis-0.42%+6.25%+4.85%+28.65%+25.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVALFCovalon TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACVRXCVRx3.0845 of 5 stars3.41.00.00.03.44.20.6INGNInogen4.259 of 5 stars3.34.00.03.91.41.71.3STXSStereotaxis0.0479 of 5 stars0.00.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVALFCovalon Technologies 0.00N/AN/AN/ACVRXCVRx 2.86Moderate Buy$14.5074.22% UpsideINGNInogen 2.50Moderate Buy$11.0070.54% UpsideSTXSStereotaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CVALF, INGN, STXS, and CVRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025CVRXCVRxWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/16/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/15/2025INGNInogenB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVALFCovalon Technologies$22.91M2.26$0.10 per share19.48$0.74 per share2.55CVRXCVRx$51.29M4.23N/AN/A$2.93 per share2.84INGNInogen$339.96M0.51N/AN/A$7.30 per share0.88STXSStereotaxis$26.92M7.40N/AN/A$0.07 per share33.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVALFCovalon Technologies$1.96M$0.0921.00∞N/A10.95%13.40%11.59%8/19/2025 (Estimated)CVRXCVRx-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)INGNInogen-$35.89M-$1.15N/AN/AN/A-8.08%-14.76%-9.01%8/5/2025 (Estimated)STXSStereotaxis-$24.05M-$0.28N/AN/AN/A-92.19%-325.86%-56.55%8/11/2025 (Estimated)Latest CVALF, INGN, STXS, and CVRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025STXSStereotaxis-$0.07N/AN/AN/A$7.75 millionN/A8/5/2025Q2 2025INGNInogen-$0.25N/AN/AN/A$90.40 millionN/A8/4/2025Q2 2025CVRXCVRx-$0.52N/AN/AN/AN/AN/A5/28/2025Q2 2025CVALFCovalon Technologies$0.01$0.01N/A$0.01$7.67 million$5.27 million5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVALFCovalon TechnologiesN/AN/AN/AN/AN/ACVRXCVRxN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVALFCovalon TechnologiesN/A8.396.09CVRXCVRx0.7114.8213.45INGNInogenN/A3.072.67STXSStereotaxisN/A1.070.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVALFCovalon TechnologiesN/ACVRXCVRx75.27%INGNInogen89.94%STXSStereotaxis45.35%Insider OwnershipCompanyInsider OwnershipCVALFCovalon TechnologiesN/ACVRXCVRx13.90%INGNInogen1.46%STXSStereotaxis17.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVALFCovalon TechnologiesN/A27.42 millionN/ANot OptionableCVRXCVRx16026.07 million22.45 millionOptionableINGNInogen1,03026.89 million26.49 millionOptionableSTXSStereotaxis13086.00 million70.72 millionNot OptionableCVALF, INGN, STXS, and CVRX HeadlinesRecent News About These CompaniesStereotaxis Sinks on Common Stock OfferingJuly 17 at 10:30 PM | baystreet.caStereotaxis Announces $12.5 Million Registered Direct Offering of Common StockJuly 17 at 8:32 AM | globenewswire.comStereotaxis, Inc. (STXS) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comStereotaxis Publishes Positive Results from MAGiC Catheter StudyJuly 10, 2025 | msn.comStereotaxis Reports Positive Initial Data From MAGiC Catheter Trial - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comStereotaxis Reports Positive Initial Data From MAGiC Catheter TrialJuly 7, 2025 | zacks.comStereotaxis: Recurring Revenue InflectionJuly 6, 2025 | seekingalpha.comStereotaxis shares data supporting Magic catheterJuly 3, 2025 | massdevice.comStereotaxis Publishes Initial Clinical Results of MAGiC Catheter in Journal of Interventional Cardiac Electrophysiology - NasdaqJuly 2, 2025 | nasdaq.comFirst Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac ElectrophysiologyJuly 1, 2025 | manilatimes.netMFirst Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac ElectrophysiologyJuly 1, 2025 | globenewswire.comStereotaxis shareholders approve board nominees and auditorMay 21, 2025 | investing.comEarnings call transcript: Stereotaxis Q1 2025 reports stable EPS, revenue growthMay 14, 2025 | uk.investing.comStereotaxis, Inc. (AMEX:STXS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comStereotaxis, Inc.: Stereotaxis Reports 2025 First Quarter Financial ResultsMay 14, 2025 | finanznachrichten.deStereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...May 14, 2025 | finance.yahoo.comStereotaxis reiterates double-digit revenue growth outlook for 2025 as recurring revenue and MAGiC adoption rampMay 13, 2025 | msn.comStereotaxis, Inc. (STXS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comStereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comStereotaxis Reports 2025 First Quarter Financial ResultsMay 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVALF, INGN, STXS, and CVRX Company DescriptionsCovalon Technologies OTCMKTS:CVALF$1.89 -0.02 (-1.05%) As of 07/17/2025 01:25 PM EasternCovalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.CVRx NASDAQ:CVRX$8.32 -0.03 (-0.32%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Inogen NASDAQ:INGN$6.45 -0.23 (-3.44%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Stereotaxis NYSEAMERICAN:STXS$2.32 -0.07 (-2.73%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Full Steam Ahead: The Bullish Case for Carnival Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
